A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including an Assessment of a Food Effect
Latest Information Update: 15 Jun 2022
At a glance
- Drugs ASP 1617 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Astellas Pharma Global Development
Most Recent Events
- 21 Jun 2021 Status changed from recruiting to completed.
- 21 May 2021 Planned End Date changed from 31 May 2021 to 30 Jun 2021.
- 21 May 2021 Planned primary completion date changed from 31 May 2021 to 30 Jun 2021.